Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
In a recent series of transactions, Paul R. Vigano, a significant shareholder in Aveanna Healthcare Holdings , Inc. (NASDAQ:AVAH), reported selling shares of the company’s common stock. The company, currently valued at $1.05 billion, has seen its stock surge 130% over the past year according to InvestingPro data. The transactions, executed over two days, March 24 and March 25, 2025, involved the sale of multiple blocks of shares.
The sales were conducted at prices ranging from $5.63 to $5.64 per share, resulting in a total transaction value of $2,816. These sales were carried out under a pre-established Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stocks.
Following these transactions, Vigano’s holdings in Aveanna Healthcare, through various entities, have been adjusted accordingly. The sales were executed by entities including J.H. Whitney VII, L.P., PSA Healthcare Investment Holding LLC, JHW Iliad Holdings LLC, PSA Iliad Holdings LLC, and JHW Iliad Holdings II LLC. These entities are collectively referred to as the Stockholder Entities.
Vigano, who is associated with J.H. Whitney Capital Partners (WA:CPAP), LLC, maintains indirect ownership of the shares involved in these transactions. The trades were part of a broader strategic plan and were not indicative of any immediate changes in the company’s operations or financial outlook.
In other recent news, Aveanna Healthcare Holdings Inc. reported financial results for the fourth quarter of 2024 that exceeded expectations. The company achieved earnings per share (EPS) of $0.05, surpassing the anticipated loss of $0.003. Revenue also outperformed forecasts, reaching $519.9 million compared to the expected $499.07 million. Additionally, Aveanna’s full-year 2024 revenue was reported at $2.024 billion, marking a 6.8% increase year-over-year. The company’s adjusted EBITDA for the fourth quarter was $55.2 million, reflecting a 42.6% increase year-over-year, with the full-year 2024 adjusted EBITDA at $183.5 million, up 31.8%.
In a separate development, Moody’s affirmed Aveanna Healthcare’s Caa1 rating while revising its outlook from stable to positive. This decision was influenced by improvements in Aveanna’s business performance and a decrease in leverage. The company’s debt-to-EBITDA ratio is expected to remain in the mid-7.0 times range over the next 12 to 18 months. Meanwhile, UBS raised its price target for Aveanna Healthcare to $4.50 from $3.20 but maintained a Sell rating on the shares. These updates reflect recent developments in Aveanna’s financial and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.